Fortrea Holdings Inc
FTRE
Company Profile
Business description
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Contact
8 Moore Drive
DurhamNC27713
USAT: +1 877 495-0816
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14,000
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.90 | 13.00 | -0.14% |
| CAC 40 | 8,339.90 | 42.53 | -0.51% |
| DAX 40 | 24,891.52 | 108.01 | -0.43% |
| Dow JONES (US) | 52,658.64 | 150.37 | 0.29% |
| FTSE 100 | 10,468.10 | 47.82 | -0.45% |
| HKSE | 25,011.25 | 330.15 | 1.34% |
| NASDAQ | 26,269.23 | 162.22 | 0.62% |
| Nikkei 225 | 66,835.54 | 1,915.97 | -2.79% |
| NZX 50 Index | 13,614.78 | 20.29 | -0.15% |
| S&P 500 | 7,572.40 | 28.81 | 0.38% |
| S&P/ASX 200 | 8,840.70 | 15.50 | -0.18% |
| SSE Composite Index | 3,882.41 | 73.17 | -1.85% |